Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS)
CNY 18.04
(-3.43%)
CNY 18.04
(-3.43%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.05 Billion CNY | -6.2% |
| 2022 | -991.39 Million CNY | -27.79% |
| 2021 | -775.78 Million CNY | -18.13% |
| 2020 | -656.72 Million CNY | 29.28% |
| 2019 | -928.59 Million CNY | -292.08% |
| 2018 | -236.83 Million CNY | -122.82% |
| 2017 | -106.29 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -242.56 Million CNY | -5.28% |
| 2024 Q1 | -206.21 Million CNY | 45.4% |
| 2024 Q2 | -230.39 Million CNY | -11.73% |
| 2023 Q2 | -173.45 Million CNY | 28.0% |
| 2023 FY | -1.05 Billion CNY | -6.2% |
| 2023 Q3 | -260.75 Million CNY | -50.33% |
| 2023 Q1 | -240.89 Million CNY | 9.33% |
| 2023 Q4 | -377.7 Million CNY | -44.85% |
| 2022 Q3 | -283.09 Million CNY | -34.16% |
| 2022 Q2 | -211 Million CNY | 4.58% |
| 2022 Q1 | -221.12 Million CNY | 13.6% |
| 2022 FY | -991.39 Million CNY | -27.79% |
| 2022 Q4 | -265.67 Million CNY | 6.15% |
| 2021 FY | -775.78 Million CNY | -18.13% |
| 2021 Q4 | -255.91 Million CNY | -44.96% |
| 2021 Q3 | -176.54 Million CNY | 3.27% |
| 2021 Q2 | -182.5 Million CNY | -15.71% |
| 2021 Q1 | -157.73 Million CNY | 14.38% |
| 2020 Q4 | -184.22 Million CNY | 4.6% |
| 2020 Q3 | -193.09 Million CNY | 0.0% |
| 2020 FY | -656.72 Million CNY | 29.28% |
| 2019 FY | -928.59 Million CNY | -292.08% |
| 2018 FY | -236.83 Million CNY | -122.82% |
| 2017 FY | -106.29 Million CNY | 0.0% |